石杉碱甲片对阿耳茨海默病记忆,认知和行为的疗效

评估石杉碱甲片治疗阿耳茨海默病的疗效及其安全性。采用多中心、前瞻性、双盲、平行、空白对照和随机方法，给５０例阿尔采末病一日两次口服石杉碱甲片４片，并给５３例阿耳茨海默病一日两次口服安慰剂片４片、共８ｗｋ。所有病人都用韦氏智力量表、简易精神状态量表、长谷川痴呆量表、日常生活能力量表、副反应量表和其他实验室检查。发现５８％（２９／５０）的石杉碱甲片服用者改善了所有的记忆、认知和行为能力，而安慰剂组仅为     

老年痴呆症的药物治疗

本文对近年用于治疗老年痴呆症的药物作一概述. 1 石杉碱甲片(tablet huperzine-A) 采用多中心,前瞻性,双盲对照和随机方法,给50例病人口服石杉碱甲片(每片含石杉碱 甲50 mg),bid,并给另53例病人口服安慰剂片,bid,治疗共8周.结果,约58%服用石杉碱片者改善了所有的记忆、认知行为能力,而安慰剂组仅为35.8%.临床试验表明,石杉碱 甲片显著增强记忆、认知行为功能[1].     

石杉碱甲片对良性衰老性遗忘症记忆和认识的疗效

目的 评估石杉碱甲片治疗良性衰老性遗忘症的疗效及其安全性。方法 采用多中心，前瞻性，双盲，空白对照和随机方法，各给50例良性衰老性遗忘症以石杉碱甲片3片（每片含50微克）或安慰剂片，一日两次口服共四周，所有病人都用韦氏记忆量表，简明精神状态量表，副反应量表和其他实验室检查。结果 发现74％（37／50）的石杉碱甲片服用改善了记忆和认知能力，而安慰剂组仅为40％（20／50），两组疗效有非常显差（χ^2=11.79,P<0.01)，而两组均无严重不良反应发生。结论 石杉碱甲片是治疗良性衰老性遗忘症的理想药物。     

石杉碱甲片对良性衰老性遗忘症记忆和认识的疗效(英文)

目的 评估石杉碱甲片治疗良性衰老性遗忘症的疗效及其安全性。方法 采用多中心，前瞻性，双盲，空白对照和随机方法，各给５０例良性衰老性遗忘症以石杉碱甲片３片（每片含５０微克）或安慰剂片，一日两次口服共四周，所有病人都用韦氏记忆量表，简明精神状态量表，副反应量表和其他实验室检查。结果 发现７４％（３７／５０）的石杉碱甲片服用者改善了记忆和认知能力，而安慰剂组仅为４０％（２０／５０），两组疗效有非常显著差（Ｘ２＝１１．７９，Ｐ＜０．０１），而两组均无严重不良反应发生。结论 石杉碱甲片是治疗良性衰老性遗忘症的理想药物。     

年痴呆症的药物治疗

本文对近年用于治疗老年痴呆症的药物作一概述。1　石杉碱甲片(ｔａｂｌｅｔｈｕｐｅｒｚｉｎｅＡ)采用多中心,前瞻性,双盲对照和随机方法,给50例病人口服石杉碱甲片(每片含石杉碱甲50ｍｇ),ｂｉｄ,并给另53例病人口服安慰剂片,ｂｉｄ,治疗共8周。结果,约58%服用石杉碱片...     

石杉碱甲胶囊与片剂随机双盲治疗轻,中度阿耳茨海默病临床疗效比较

目的:比较石杉碱甲胶囊与石杉碱甲片剂治疗轻、中度阿耳茨海默病的疗效。方法:采用随机双盲对照法,胶囊组17例,片剂组15例,按胶囊A 片剂B(安慰剂)和胶囊B(安慰剂) 片剂A两组交叉服药,剂量为3粒或3片(每粒或片含石杉碱甲0.05mg),一日2次,疗程8周。用量表评分,观察疗效。结果:MMSE、HDSR评分治疗后均有显著增加,但两组增值分别为1.76±1.64和1.73±2.02,无显著差异(P>0.05);胶囊组和片剂组的总有效率分别为58.82％和66.66％,无显著差异(P>0.05)。MQ评分治疗后均有显著升高(P<0.05,P<0.01),但两组治疗后增值分别为7.53±6.72和 9.80±14.51,无明显差异(P>0.05)。两组总有效率分别为52.94％和60.0％,无显著差异。本研究中未见明显不良反应。结论:石杉碱甲胶囊与片剂治疗轻、中度阿耳茨海默病疗效同等有效。     

石杉碱甲胶囊及片剂治疗阿尔采末病

目的;比较石杉碱甲胶囊和片剂对阿尔采末病的疗效和安全性。方法：采用双盲双模拟法将入选的６０例阿尔采末病人随机等分两组,胶囊组每次口服石杉碱甲胶囊４粒和安慰剂片４片;片剂组每次口服石杉碱甲片４片和安慰剂胶囊４粒,两组均每日两次;６０日为一疗程。     

石杉碱甲胶囊及片剂治疗阿尔采末病(英文)

比较石杉碱甲胶囊和片剂对阿尔采末病的疗效和安全性．方法：采用双盲双模拟法将入选的６０例阿尔采末病人随机等分两组,胶囊组每次口服石杉碱甲胶囊４粒和安慰剂片４片;片剂组每次口服石杉碱甲片（哈伯因）４片和安慰剂胶囊４粒,两组均每日两次,６０日为一疗程．所有病人都测量ＷＭＳ,ＭＭＳ,ＨＤＳ－Ｒ,ＩＡＤＬ,ＧＢＳ痴呆综合征量表和各种检查以及氧自由基．结果：两组所有心理量表值疗后均有显著改善（Ｐ＜０．０１）,而两组间无明显差异（Ｐ＞０．０５）,且等效检验合格;两组的自由基病理变化疗后也明显减轻,但也无组间差异（Ｐ＞０．０５）;两组未发生严重不良反应．结论：石杉碱甲胶囊和片剂治疗阿尔采末病时疗效和安全性相等。     

石杉碱甲片治疗阿耳茨海默病的临床疗效

目的；观察石杉碱甲片治疗阿耳茨海默病（ＡＤ）临床疗效。方法：选择符合ＩＣＤ－１０诊断标准的４１例ＡＤ患者，随机给其中治疗组（２３例）投用石杉碱甲０．１５ｍｇｂｉｄ对照组（１８例）投用砒啦西坦１．２ｇｂｉｄ，８ｗｋ为一疗程，疗前，疗后分别进行韦工记忆量表（ＷＭＳ）和简明智力量表（ＭＭＳＥ）的检测和评分比较，结果：两组治疗前，后ＷＭＳ的记忆商（ＭＱ）和ＭＭＳＥ总评分，自身比较有显著性差异（治疗组Ｐ〈０     

石杉碱甲治疗轻中度阿尔茨海默病的临床研究

目的评价石杉碱甲治疗阿尔茨海默病(Alzheimer's disease,AD)的临床疗效和安全性。方法将60例轻、中度AD患者随机分为石杉碱甲组(治疗组)和安慰剂组(对照组),各30例。治疗组给予石杉碱甲片0.2 mg,2次/d口服;对照组口服安慰剂,2次/d口服。疗程均为12周。治疗前后分别测定记忆商(Memory Quo-tient,MQ)、简易智力状态检查(Mini-mental state examination,MMSE)、长谷川痴呆修正量表(HDS-R)、工具性日常生活活动能力量表(ADL)的变化。结果治疗12周后,治疗组AD患者MQ、MMSE积分显著提高(P<0.01),与对照组治疗后比较,差异有统计学意义(P<0.01);ADL积分降低,与治疗前比较,差异有统计学意义(P<0.01),与对照组治疗后比较,差异有统计学意义(P<0.01)。结论石杉碱甲片对轻、中度AD有较好疗效,且副作用较少,是安全性较好的药物。     

石杉碱甲胶囊提高34对青春期学习记忆和学习成绩

研究石杉碱甲胶囊对初中学生记和学习成绩的效能。方法：采用双盲法,按照心理健康正常,记忆商接近,同班,同性别的要求。将６８例初中学生配对成两组,随机各给石杉碱甲胶囊２粒或空白胶囊２片,一日两次口服,４周为一疗程,以记商及语文英语和数学以及上述三课均分为观测指标评定疗效。结果;石杉碱甲胶囊组疗末的记商明显高于空白组,语文成绩也明显提高。     

氟哌噻吨美利曲辛联合PPI制剂治疗非糜烂性胃食管反流病的近期疗效及安全性

目的观察氟哌噻吨美利曲辛联合PPI制剂治疗非糜烂性胃食管反流病患者躯体症状和精神症状的效果及安全性。方法前瞻性选取我院消化内科住院部/门诊2014年1月至2016年1月收治的120例确诊为非糜烂性胃食管反流病患者,采用随机数字表法将其分为2组,每组60例,对照组在生活干预和心理疏导基础上予以埃索美拉唑,观察组加用氟哌噻吨美利曲辛,对比两组各项临床症状改善情况、疗效、不良反应及焦虑和抑郁改善情况。结果两组患者治疗后RDQ评分较治疗前均明显降低(P<0.01),且观察组明显低于对照组(P<0.01);观察组总有效率为86.67%,高于对照组的68.33%(P<0.05);观察组不良反应发生率为5.00%,明显低于对照组的20.00%(P<0.05);两组患者治疗后HAMD评分和HAMA评分较治疗前均明显降低(P<0.01),且观察组两项评分均低于对照组(P<0.01)。结论氟哌噻吨美利曲辛联合PPI可明显改善非糜烂性胃食管反流病患者躯体症状和精神症状,效果确切,且安全性高,可作为临床首选的治疗方案之一。     

帕利哌酮缓释片联合选择性5-羟色胺再摄取抑制剂治疗难治性强迫障碍疗效观察

目的探讨帕利哌酮缓释片作为增效剂治疗难治性强迫障碍的疗效和耐受性。方法将59例难治性强迫症患者随机分为研究组和对照组。研究组29例,给予帕利哌酮缓释片(3~6 mg)联合选择性5-羟色胺再摄取抑制剂(SSRIs);对照组30例,单用SSRIs。疗程为8周。在治疗前与治疗后4、8周末,采用耶鲁-布朗强迫量表(Y-BOCS)和副反应量表(TESS)评定疗效和不良反应。结果治疗第8周末,研究组和对照组的有效率分别为89.66%和46.67%,两组比较差异有统计学意义(P<0.05);研究组Y-BOCS评分为12.86±5.36,较治疗前(27.28±4.72)显著改善,且明显低于对照组(21.47±5.98),差异均有统计学意义(P<0.01)。两组不良反应程度均较轻微,TESS评分比较差异无统计学意义(P>0.05)。结论小剂量帕利哌酮缓释片联合SSRIs治疗难治性强迫症较单用SSRIs有效,且安全性相当。     

石杉碱甲药剂学相关研究进展

石杉碱甲为高效、高选择性、可逆的乙酰胆碱酯酶抑制剂,由于其在治疗阿尔茨海默病方面的显著疗效,引起世界各国药学工作者广泛关注和研究.石山碱甲虽为难溶性生物碱,但其口服吸收迅速而完全,现有的剂型研究主要集中在亲水凝胶骨架片、缓释包衣小丸、透皮缓释贴剂、鼻用凝胶脑靶向制剂以及注射用缓释微球等缓控释给药系统,且多数经体内外评价证实具有显著的缓控释特征.文中综述了石杉碱甲药剂学相关的研究进展,包括其基本理化性质、体内外吸收和代谢动力学以及新型给药系统(尤其是缓控释制剂)等,以期为进一步开发高效、低毒、稳定、方便的新产品提供剂型选择依据和处方研究参考.     

A randomized controlled study comparing rofecoxib, diclofenac sodium, and placebo in post-bunionectomy pain

OBJECTIVE: The relative efficacy of rofecoxib, diclofenac sodium, and placebo were compared in the treatment of acute pain after bunionectomy surgery. RESEARCH DESIGN AND METHODS: This was a double-blind, randomized, two-part study of 252 patients with moderate-to-severe pain the day after first metatarsal bunionectomy. Patients were treated with a single dose of rofecoxib 50 mg (N = 85), enteric-coated diclofenac sodium 100 mg (N = 85), or placebo (N = 82) on study Day 1 (Part I), and subsequently with daily rofecoxib 50 mg or placebo (diclofenac patients switched to placebo) over study Days 2-5 (Part II). Patients rated their pain at 16 time points over the first 24 h. Primary endpoint was total pain relief over 8 h (TOPAR8). Pre-specified secondary endpoints on Day 1 included onset of analgesia, peak pain relief, and duration of response. For Part II, supplemental analgesia use with rofecoxib compared to placebo was pre-specified for analysis over Days 2-5, with the focus on Days 2-3. Adverse experiences were recorded over Days 1-5. RESULTS: For TOPAR8 scores, rofecoxib 50 mg was significantly more effective than placebo (9.5 vs. 3.7, p < 0.001) and diclofenac (9.5 vs. 5.0, p < 0.001). Onset of analgesia was more rapid with rofecoxib than placebo (p = 0.003) and diclofenac (p = 0.019); proportion of patients achieving onset within 4 h with rofecoxib, diclofenac, and placebo was 46%, 27%, and 23%, respectively. Peak pain relief was greater with rofecoxib (1.8) than diclofenac (1.2, p = 0.004) and placebo (1.0, p < 0.001). Diclofenac and placebo patients required supplemental analgesia sooner than rofecoxib patients (2:03 h vs. 4:02 h, p < 0.001 and 1:41 h vs. 4:02 h, p < 0.001). Rofecoxib patients used significantly less (p < 0.001) supplemental analgesia than placebo patients over Days 2-3 (1.1 tablets/day vs. 2.1 tablets/day) and Days 2-5 (0.9 tablets/day vs. 1.8 tablets/day). No significant differences in adverse experiences between treatments were seen. CONCLUSION: Rofecoxib 50 mg was significantly more effective than placebo on all measures of treatment of post-bunionectomy pain. Rofecoxib 50 mg was significantly more effective than diclofenac sodium 100 mg based on Day 1 endpoints of total pain relief, onset time, and duration of response. All study medications were generally well tolerated.     

二活附子方治疗强直性脊柱炎的临床疗效及安全性评价

目的：评价中药二活附子方治疗强直性脊柱炎( ankylosing spondylitis, AS)的临床疗效及安全性。方法采用前瞻性随机对照临床试验,将78例AS患者随机分入观察组和对照组,观察组给予二活附子方,对照组给予柳氮磺胺吡啶片口服,疗程12周,疗效评价采用ASAS20、ASAS40及BASDAI50标准及中医证候疗效评价标准。观察治疗前后患者Bath强直性脊柱炎疾病活动指数( BASDAI)、Bath强直性脊柱炎功能指数( BASFI)、Bath强直性脊柱炎测量指数( BASMI)、脊柱痛评分、夜间痛评分、患者总体评价( PGA)、红细胞沉降率( ESR)及C反应蛋白( CRP)等指标。结果治疗4周后,观察组达到ASAS20标准的患者例数多于对照组(P<0．05)。治疗12周后,观察组达到ASAS20、ASAS40、BASDAI50标准的患者例数多于对照组(P<0．05);中医证候疗效观察组高于对照组(P<0．05);两组治疗后中医证候积分、BASDAI、BASFI、脊柱痛评分、夜间痛评分、PGA均优于治疗前(P<0．05,P<0．01),且观察组上述指标改善情况均优于对照组(P<0．05);两组治疗后ESR、CRP较治疗前降低(P<0．05);两组不良反应发生率比较,差异无统计学意义(P>0．05)。结论应用二活附子方治疗AS疗效确切且安全性较高。     

Budesonide enema in pouchitis--a double-blind, double-dummy, controlled trial

BACKGROUND: Pouchitis has been suggested to be a recurrence of ulcerative colitis in a colon-like mucosa. Topical steroids are a valid therapeutic alternative for distal forms of ulcerative colitis. AIM: To investigate the efficacy and tolerability of budesonide enema in the treatment of pouchitis compared with oral metronidazole. MATERIALS AND METHODS: Twenty-six patients with an active episode of pouchitis (defined as a pouchitis disease activity index score >or= 7) and no treatment during the previous month were randomized to receive either budesonide enema (2 mg/100 mL at bedtime) plus placebo tablets or oral metronidazole (0.5 g b.d.) plus placebo enema in a prospective, double-blind, double-dummy, 6-week, controlled trial. RESULTS: Based on the intention-to-treat principle, we detected a significant improvement in disease activity at the end of the first week with both drugs (P < 0.01). After that, improvement was moderated until stabilization at 4 weeks in both treatments. The per protocol analysis showed that both drugs had similar efficacy in terms of disease activity, clinical and endoscopic findings. Fifty-eight per cent and 50% of patients improved (decrease in pouchitis disease activity index >or= 3) with budesonide enema and metronidazole, respectively (odds ratio, 1.4; confidence interval, 0.2-8.9). Adverse effects were observed in 57% of patients given metronidazole and in 25% of patients given budesonide. CONCLUSIONS: Budesonide enemas are an alternative treatment for active pouchitis, with similar efficacy but better tolerability than oral metronidazole.